Analysis of Second Primary Tumours in Cutaneous Lymphoma Populations.

IF 2.2 4区 医学 Q3 ONCOLOGY
Cancer Investigation Pub Date : 2026-10-01 Epub Date: 2026-06-30 DOI:10.1080/07357907.2026.2675664
Shuaijun Zou, Ruiqian Yao, Xiaoyan Yang, Erwen Kou, Sijia Huang, Hao Zhu, Liangzhe Wang, Julin Gu, Yuanjie Zhu
{"title":"Analysis of Second Primary Tumours in Cutaneous Lymphoma Populations.","authors":"Shuaijun Zou, Ruiqian Yao, Xiaoyan Yang, Erwen Kou, Sijia Huang, Hao Zhu, Liangzhe Wang, Julin Gu, Yuanjie Zhu","doi":"10.1080/07357907.2026.2675664","DOIUrl":null,"url":null,"abstract":"<p><p>The elevated incidence of second primary tumors (SPTs) has been reported in certain subtypes of cutaneous T-cell lymphomas (CTCLs) and cutaneous B-cell lymphomas (CBCLs), but remains unclear for overall primary cutaneous lymphomas (PCLs). Using Surveillance, Epidemiology and End Results (SEER) data, we analyzed 20,970 patients with PCLs and evaluated standardized incidence ratios (SIRs) and survival outcomes of SPTs stratified by lymphoma subtype (indolent vs. aggressive). A total of 2,589 SPTs were identified (SIR = 1.40, 95% CI 1.35-1.45), with significantly elevated risks across sex, ethnicity, stage, latency, year of diagnosis, and treatment. Both indolent and aggressive CTCLs were associated with increased SPT risk, with SIRs of 1.27 (1.16-1.39) and 1.38 (1.11-1.69), respectively. Lymphatic and hematopoietic malignancies predominated in indolent CTCLs, along with thyroid cancer, whereas aggressive CTCLs were mainly associated with extranodal non-Hodgkin lymphoma and myeloma. Increased SPT incidence was also observed in indolent and aggressive CBCLs (SIR = 1.49 and 1.38), with indolent CBCLs showing a broad SPT spectrum including lung cancer and cutaneous melanoma. Patients younger than 30 years, with stage I disease or aggressive PCLs, had decreased age-adjusted overall and disease-specific survival, indicating a need for more intensive surveillance.</p>","PeriodicalId":9463,"journal":{"name":"Cancer Investigation","volume":" ","pages":"984-993"},"PeriodicalIF":2.2000,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Investigation","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/07357907.2026.2675664","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/6/30 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

The elevated incidence of second primary tumors (SPTs) has been reported in certain subtypes of cutaneous T-cell lymphomas (CTCLs) and cutaneous B-cell lymphomas (CBCLs), but remains unclear for overall primary cutaneous lymphomas (PCLs). Using Surveillance, Epidemiology and End Results (SEER) data, we analyzed 20,970 patients with PCLs and evaluated standardized incidence ratios (SIRs) and survival outcomes of SPTs stratified by lymphoma subtype (indolent vs. aggressive). A total of 2,589 SPTs were identified (SIR = 1.40, 95% CI 1.35-1.45), with significantly elevated risks across sex, ethnicity, stage, latency, year of diagnosis, and treatment. Both indolent and aggressive CTCLs were associated with increased SPT risk, with SIRs of 1.27 (1.16-1.39) and 1.38 (1.11-1.69), respectively. Lymphatic and hematopoietic malignancies predominated in indolent CTCLs, along with thyroid cancer, whereas aggressive CTCLs were mainly associated with extranodal non-Hodgkin lymphoma and myeloma. Increased SPT incidence was also observed in indolent and aggressive CBCLs (SIR = 1.49 and 1.38), with indolent CBCLs showing a broad SPT spectrum including lung cancer and cutaneous melanoma. Patients younger than 30 years, with stage I disease or aggressive PCLs, had decreased age-adjusted overall and disease-specific survival, indicating a need for more intensive surveillance.

皮肤淋巴瘤人群第二原发肿瘤的分析。
第二原发肿瘤(SPTs)的发生率增高已经在皮肤t细胞淋巴瘤(CTCLs)和皮肤b细胞淋巴瘤(CBCLs)的某些亚型中有报道,但对于所有原发性皮肤淋巴瘤(PCLs)的发生率仍不清楚。使用监测、流行病学和最终结果(SEER)数据,我们分析了20,970例pcl患者,并评估了按淋巴瘤亚型(惰性与侵袭性)分层的spt的标准化发病率(SIRs)和生存结果。共鉴定出2589例spt (SIR = 1.40, 95% CI 1.35-1.45),不同性别、种族、分期、潜伏期、诊断年份和治疗的spt风险显著升高。惰性和侵袭性ctcl均与SPT风险增加相关,SIRs分别为1.27(1.16-1.39)和1.38(1.11-1.69)。淋巴和造血恶性肿瘤在惰性ctcl和甲状腺癌中占主导地位,而侵袭性ctcl主要与结外非霍奇金淋巴瘤和骨髓瘤相关。在惰性和侵袭性cbcl中也观察到SPT发生率增加(SIR = 1.49和1.38),其中惰性cbcl表现出广泛的SPT谱,包括肺癌和皮肤黑色素瘤。年龄小于30岁,患有I期疾病或侵袭性pcl的患者,年龄调整后的总体生存率和疾病特异性生存率下降,表明需要更强化的监测。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Cancer Investigation
Cancer Investigation 医学-肿瘤学
CiteScore
3.80
自引率
4.20%
发文量
71
审稿时长
8.5 months
期刊介绍: Cancer Investigation is one of the most highly regarded and recognized journals in the field of basic and clinical oncology. It is designed to give physicians a comprehensive resource on the current state of progress in the cancer field as well as a broad background of reliable information necessary for effective decision making. In addition to presenting original papers of fundamental significance, it also publishes reviews, essays, specialized presentations of controversies, considerations of new technologies and their applications to specific laboratory problems, discussions of public issues, miniseries on major topics, new and experimental drugs and therapies, and an innovative letters to the editor section. One of the unique features of the journal is its departmentalized editorial sections reporting on more than 30 subject categories covering the broad spectrum of specialized areas that together comprise the field of oncology. Edited by leading physicians and research scientists, these sections make Cancer Investigation the prime resource for clinicians seeking to make sense of the sometimes-overwhelming amount of information available throughout the field. In addition to its peer-reviewed clinical research, the journal also features translational studies that bridge the gap between the laboratory and the clinic.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书